Ser21

Site Information
NKGLLsDsMtDVPVD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3175178

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 )
Disease tissue studied:	bone cancer ( 19 ) , osteosarcoma ( 19 ) , breast cancer ( 5 , 6 , 11 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 5 ) , cervical cancer ( 20 ) , cervical adenocarcinoma ( 20 ) , leukemia ( 13 ) , acute myelogenous leukemia ( 13 ) , lung cancer ( 8 , 11 , 16 ) , non-small cell lung cancer ( 11 ) , non-small cell lung adenocarcinoma ( 8 ) , ovarian cancer ( 5 ) , multiple myeloma ( 18 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	293E (epithelial) ( 14 ) , A498 (renal) ( 17 ) , B lymphocyte-blood ( 18 ) , breast ( 2 , 5 ) , BT-20 (breast cell) ( 11 ) , BT-549 (breast cell) ( 11 ) , Calu 6 (pulmonary) ( 11 ) , CL1-0 (pulmonary) ( 16 ) , CL1-1 (pulmonary) ( 16 ) , CL1-2 (pulmonary) ( 16 ) , CL1-5 (pulmonary) ( 16 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 12 ) , Flp-In T-Rex-293 (epithelial) ( 12 ) , H2009 (pulmonary) ( 11 ) , H2077 (pulmonary) ( 11 ) , H2887 (pulmonary) ( 11 ) , H322M (pulmonary) ( 11 ) , HCC1937 (breast cell) ( 11 ) , HCC366 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 11 ) , HeLa (cervical) ( 1 , 4 , 10 , 21 , 25 , 26 ) , HeLa S3 (cervical) ( 20 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , HOP62 (pulmonary) ( 11 ) , HUES-9 ('stem, embryonic') ( 15 ) , Jurkat (T lymphocyte) ( 9 , 24 ) , K562 (erythroid) ( 10 , 21 ) , KG-1 (myeloid) ( 13 ) , liver ( 7 ) , LOU-NH91 (squamous) ( 11 ) , lung ( 8 ) , MCF-7 (breast cell) ( 11 ) , MDA-MB-231 (breast cell) ( 11 ) , MDA-MB-468 (breast cell) ( 11 ) , NCI-H1395 (pulmonary) ( 11 ) , NCI-H1568 (pulmonary) ( 11 ) , NCI-H1648 (pulmonary) ( 11 ) , NCI-H2030 (pulmonary) ( 11 ) , NCI-H322 (pulmonary) ( 11 ) , NCI-H460 (pulmonary) ( 11 , 22 ) , NCI-H647 (pulmonary) ( 11 ) , ovary ( 5 ) , U2OS (bone cell) ( 19 ) , WM115 (melanocyte) ( 23 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	ischemia ( 5 ) , metastatic potential ( 16 ) , nocodazole ( 20 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
7	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
8	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
9	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
10	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
13	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
14	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
15	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
16	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
17	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
18	Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90 20230923 Curated Info
19	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
20	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
21	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
22	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
23	Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31 19362540 Curated Info
24	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
25	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
26	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info